Literature DB >> 10844516

C1q receptors.

P Eggleton1, A J Tenner, K B Reid.   

Abstract

Mesh：

Substances：

Year:  2000        PMID： 10844516      PMCID： PMC1905565          DOI： 10.1046/j.1365-2249.2000.01218.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN： 0009-9104            Impact factor:   4.330


× No keyword cloud information.
  61 in total

Review 1.  The classical complement pathway: activation and regulation of the first complement component.

Authors:  N R Cooper
Journal:  Adv Immunol       Date:  1985       Impact factor: 3.543

2.  Characterization of C1q-binding material released from the membranes of Raji and U937 cells by limited proteolysis with trypsin.

Authors:  A Erdei; K B Reid
Journal:  Biochem J       Date:  1988-10-15       Impact factor: 3.857

3.  Localization of the binding site for the human high-affinity Fc receptor on IgG.

Authors:  A R Duncan; J M Woof; L J Partridge; D R Burton; G Winter
Journal:  Nature       Date:  1988-04-07       Impact factor: 49.962

4.  Primate erythrocyte-immune complex-clearing mechanism.

Authors:  J B Cornacoff; L A Hebert; W L Smead; M E VanAman; D J Birmingham; F J Waxman
Journal:  J Clin Invest       Date:  1983-02       Impact factor: 14.808

Review 5.  Functions associated with the C1q receptor.

Authors:  B Ghebrehiwet
Journal:  Behring Inst Mitt       Date:  1989-07

6.  Chemical and hydrodynamic characterization of the human leucocyte receptor for complement subcomponent C1q.

Authors:  R Malhotra; R B Sim
Journal:  Biochem J       Date:  1989-09-01       Impact factor: 3.857

7.  Modulation of FcR function by complement: subcomponent C1q enhances the phagocytosis of IgG-opsonized targets by human monocytes and culture-derived macrophages.

Authors:  D A Bobak; T A Gaither; M M Frank; A J Tenner
Journal:  J Immunol       Date:  1987-02-15       Impact factor: 5.422

8.  Complement activation during systemic lupus erythematosus. C3a and C5a anaphylatoxins circulate during exacerbations of disease.

Authors:  H M Belmont; P Hopkins; H S Edelson; H B Kaplan; R Ludewig; G Weissmann; S Abramson
Journal:  Arthritis Rheum       Date:  1986-09

9.  Evidence that C1q binds specifically to CH2-like immunoglobulin gamma motifs present in the autoantigen calreticulin and interferes with complement activation.

Authors:  H Kovacs; I D Campbell; P Strong; S Johnson; F J Ward; K B Reid; P Eggleton
Journal:  Biochemistry       Date:  1998-12-22       Impact factor: 3.162

10.  The role of beta-hydroxyaspartate and adjacent carboxylate residues in the first EGF domain of human factor IX.

Authors:  D J Rees; I M Jones; P A Handford; S J Walter; M P Esnouf; K J Smith; G G Brownlee
Journal:  EMBO J       Date:  1988-07       Impact factor: 11.598
View more
  29 in total

Review 1.  Complement activation in the context of stem cells and tissue repair.

Authors:  Ingrid U Schraufstatter; Sophia K Khaldoyanidi; Richard G DiScipio
Journal:  World J Stem Cells       Date:  2015-09-26       Impact factor: 5.326

2.  Classical pathway complement activation on human endothelial cells.

Authors:  Wei Yin; Berhane Ghebrehiwet; Babette Weksler; Ellinor I Peerschke
Journal:  Mol Immunol       Date:  2006-12-14       Impact factor: 4.407

Review 3.  Production of complement components by cells of the immune system.

Authors:  R Lubbers; M F van Essen; C van Kooten; L A Trouw
Journal:  Clin Exp Immunol       Date:  2017-03-24       Impact factor: 4.330

4.  Increased susceptibility of C1q-deficient mice to Salmonella enterica serovar Typhimurium infection.

Authors:  Joanna Warren; Pietro Mastroeni; Gordon Dougan; Mahdad Noursadeghi; Jonathan Cohen; Mark J Walport; Marina Botto
Journal:  Infect Immun       Date:  2002-02       Impact factor: 3.441

5.  The multicompartmental p32/gClqR as a new target for antibody-based tumor targeting strategies.

Authors:  David Sánchez-Martín; Angel M Cuesta; Valentina Fogal; Erkki Ruoslahti; Luis Alvarez-Vallina
Journal:  J Biol Chem       Date:  2010-12-14       Impact factor: 5.157

6.  The non-inflammatory role of C1q during Her2/neu-driven mammary carcinogenesis.

Authors:  Silvio Bandini; Marco Macagno; Albana Hysi; Stefania Lanzardo; Laura Conti; Amanda Bello; Federica Riccardo; Roberto Ruiu; Irene Fiore Merighi; Guido Forni; Manuela Iezzi; Elena Quaglino; Federica Cavallo
Journal:  Oncoimmunology       Date:  2016-11-08       Impact factor: 8.110

7.  C1qRP (CD93) expression on peripheral blood monocytes in patients with systemic lupus erythematosus.

Authors:  Frank Moosig; Erika Fähndrich; Anja Knorr-Spahr; Sebastian Böttcher; Matthias Ritgen; Rainald Zeuner; Michael Kneba; Johann O Schröder
Journal:  Rheumatol Int       Date:  2006-05-04       Impact factor: 2.631

8.  C1q limits dendritic cell differentiation and activation by engaging LAIR-1.

Authors:  Myoungsun Son; Frances Santiago-Schwarz; Yousef Al-Abed; Betty Diamond
Journal:  Proc Natl Acad Sci U S A       Date:  2012-10-23       Impact factor: 11.205

Review 9.  Current status and issues of C1q nephropathy.

Authors:  Akiko Mii; Akira Shimizu; Yukinari Masuda; Emiko Fujita; Kaoru Aki; Masamichi Ishizaki; Shigeru Sato; Adam Griesemer; Yuh Fukuda
Journal:  Clin Exp Nephrol       Date:  2009-04-17       Impact factor: 2.801

Review 10.  Fundamental role of C1q in autoimmunity and inflammation.

Authors:  Myoungsun Son; Betty Diamond; Frances Santiago-Schwarz
Journal:  Immunol Res       Date:  2015-12       Impact factor: 2.829
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.